Samuel Agahiu, MD
Nephrology · Englewood, NJNPI 1992967020
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,208 of the $6,416 with a category attached, or 81.2%. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.
Across 260 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Amgen$1K
- Vifor Pharma, Inc.$571
- Travere Therapeutics, Inc.$542
- Otsuka America Pharmaceutical, Inc.$528
- Bayer$467
- plus $2K from 14 others
What the payments were for
- Consulting fees$1,19019%
- Travel & lodging$80%
- Food & beverage$5,20881%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $1,156 |
| Amgen(2 entities) | 52 | $1,110 |
| Vifor Pharma, Inc. | 35 | $571 |
| Travere Therapeutics, Inc. | 26 | $542 |
| Otsuka America Pharmaceutical, Inc. | 22 | $528 |
| Bayer | 29 | $467 |
| AstraZeneca | 14 | $404 |
| Ardelyx, Inc. | 14 | $360 |
| Aurinia Pharma U.S., Inc. | 8 | $295 |
| Calliditas Therapeutics US Inc. | 9 | $201 |
| Novartis | 9 | $162 |
| Novo Nordisk | 3 | $138 |
| Boehringer Ingelheim | 9 | $136 |
| Akebia Therapeutics Inc | 9 | $125 |
| Fresenius USA Marketing, Inc. | 7 | $112 |
| ANI Pharmaceuticals, Inc. | 3 | $43 |
| Recor Medical Inc | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| OPKO Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,416 in reported general payments places this provider in the 85th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $76,961 |
| FarxigaDapagliflozin Propanediol | 77 | $62,307 |
| KerendiaFinerenone | 26 | $16,699 |
| Sevelamer Carbonate | 40 | $3,473 |
| Calcium Acetate | 17 | $1,251 |
| Torsemide | 40 | $753 |
| Hydralazine Hcl | 20 | $433 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 15 | $289 |
| Allopurinol | 27 | $289 |
| Amlodipine Besylate | 32 | $286 |
| Losartan Potassium | 30 | $248 |
| Furosemide | 28 | $180 |
| Tamsulosin Hcl | 11 | $79 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $136 | $76,96182 claims |
| AstraZenecaFarxiga | $404 | $62,30777 claims |
| BayerKerendia | $467 | $16,69926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Englewood
- Louis JanEnglewood$25K
- Marc ZelkowitzEnglewood$17K
- Gerald GrodsteinEnglewood$7K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.